Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Esperion Therapeutics Inc. shares valued at $924 were sold by Warren Eric on Sep 20 ’23. At $1.25 per share, Warren Eric sold 742 shares. The insider’s holdings dropped to 68,318 shares worth approximately $0.18 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Warren Eric sold 243 shares, netting a total of over 344 in proceeds. Following the sale of shares at $1.41 each, the insider now holds 69,060 shares.
Before that, Warren Eric had sold 106 shares from its account. In a trade valued at $168, the Chief Commercial Officer traded Esperion Therapeutics Inc. shares for $1.58 each. Upon closing the transaction, the insider’s holdings decreased to 106 shares, worth approximately $0.18 million.
As published in a research note from BofA Securities on January 03, 2024, Esperion Therapeutics Inc. [ESPR] has been rated down from a Buy to a Neutral. As of August 01, 2023, Northland Capital has increased its “an Under perform” rating to a “Market perform” for ESPR. Earlier on June 15, 2023, BofA Securities upgraded its rating. Their new recommendation was “a Buy” for ESPR stock which previously was a “an Underperform”.
Analyzing ESPR Stock Performance
During the last five days, there has been a surge of approximately 19.63%. Over the course of the year, Esperion Therapeutics Inc. shares have dropped approximately -12.37%. Shares of the company reached a 52-week high of $3.34 on 01/12/24 and a 52-week low of $1.65 on 01/19/24. A 50-day SMA is recorded $2.37, while a 200-day SMA reached $1.69. Nevertheless, trading volume fell to 11.93 million shares from 27.46 million shares the previous day.
Support And Resistance Levels for Esperion Therapeutics Inc. (ESPR)
According to the 24-hour chart, there is a support level at 2.49, which, if violated, would cause prices to drop to 2.37. In the upper region, resistance lies at 2.77. The next price resistance is at 2.93. RSI (Relative Strength Index) is 59.47 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.41, which suggests the price will decrease in the coming days. Percent R is at 32.69%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.
Is Esperion Therapeutics Inc. subject to short interest?
Stocks of Esperion Therapeutics Inc. saw a sharp steep in short interest on Feb 29, 2024 dropping by -3.12 million shares to 16.95 million. Data from Yahoo Finance shows that the short interest on Jan 31, 2024 was 20.07 million shares. A decline of -18.41% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 3.47 of the overall float, the days-to-cover ratio (short ratio) decline to 3.47.
